Introduction
According to the World Health Organization, tuberculosis (TB) is second only to Human Immunodeficiency Virus (HIV) as the greatest killer worldwide due to a single infectious agent. 1 The numbers reported at the Global Tuberculosis Report for 2014 are highlighting the severity of the disease. During 2013, 9 million people fell ill with TB and 1.5 million people died. Whilst TB is treatable and curable, standard anti-TB drugs, like isoniazid (INH) and rifampicin (RMP), have been used for decades, and resistance to the medicines is widespread. Clinical strains that are resistant to a single anti-TB drug have been documented in every country surveyed giving rise to multidrug-resistant tuberculosis (MDR-TB), extensively drugresistant tuberculosis (XDR-TB) and the recently reported totally drug-resistant tuberculosis (TDR-TB). [2] [3] [4] In addition, the standard treatment for adult respiratory TB is a regimen of drugs developed many years ago and is connected with several adverse effects like hepatotoxicity, skin reactions, gastrointestinal and neurological disorders. 5 Among them hepatotoxicity is the most serious one 6 , directing the current research towards the need to enrich the pipeline of available drugs against TB, preferably with candidates offering lower cytotoxicity and with new mode of action in comparison to existing drugs.
On the contrary, various opportunistic human infections are caused by nontuberculous mycobacteria (NTM) and, according to the predictions, they will continue to increase their incidence at least up to year 2050 mainly due to an increasing elderly population. 7 The treatment of NTM caused infections is complicated and involves multiple medications due to the high levels of natural and acquired antibiotic resistance. Furthermore, their current treatment share limited efficacy 8 , and therefore there is a need for new therapeutic strategies to be developed. Moreover, severe hospital-acquired infections can be caused due to notable drug-resistance complications that have been reported for Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae and Enterococci. 9 Salicylanilides (2-hydroxy-N-phenylbenzamides) have been the subject of several medicinal chemistry studies due to their significant in vitro antimicrobial and antifungal activities. [10] [11] [12] A number of salicylanilide derivatives have been developed so far with proven activity against Mycobacterium tuberculosis (Mtb) and INH-resistant strains. [13] [14] [15] However, the precise molecular mode of action of salicylanilides is not clear. It has been previously reported that a free phenolic hydroxyl on the salicylic acid moiety is required for activity and suggested that they might function as proton shuttles that kill bacterial cells by destroying the cellular proton gradient. 16 On the other hand, salicylanilides and their ester derivatives have been reported to act as moderate inhibitors of mycobacterial and human methionine aminopeptidases and may target the function of mycobacterial isocitrate lyase which could enhance its efficacy due to its particular relevance to mycobacterial latency. 17 These findings have suggested that salicylanilides affect multiple targets to exert their antimicrobial properties. Furthermore, salicylanilide esters, carbamates and additional derivatives resulting from their conjugation with existing antimicrobial agents, have been suggested to work as pro-drugs that are hydrolysed in order to express their activity. 18 Although salicylanilides and their derivatives (esters, carbamates etc.) are very potent against Mtb, they often share a non-preferable cytotoxic profile. 16, 19 This drawback has limited their utility as potential therapeutics so far. Recent work has focused on the discovery of salicylanilide derivatives with decreased cytotoxicity and, under this concept, novel 2-(phenylcarbamoyl)phenyl 4-substituted benzoates were synthesized and found to be active against several mycobacteria (0.125-8 μM) while they exhibited no cytotoxicity at concentrations of up to 50 μM against a hepatocyte cell line (HepG2). 20 The esterification products of 5-halogenated salicylanilides with 4-substituted benzoic acids were found to be, not only more potent inhibitors of Mtb growth but also to share a preferable cytotoxic profile in contrast with the parent salicylanilides. The increased lipophilicity of the afforded derivatives limited their solubility in aqueous media and hence their drugability.
Our ongoing efforts explore the influence of different substitutions on the parent structure of salicylanilides, in terms of their activity and cytotoxicity. The introduction of several substituents is under investigation. In general, it has been previously reported that an electron withdrawing group is favored in the aniline part while the influence of the substituents from the acyl moiety is more complex. 21 The best substituents of the parent salicylanilide structure reported so far is -Br or -Cl atoms in position 5 of the salicylic acid part while a -CF 3 group is favoured in position 4 of the aniline part. More specifically, 5-bromo-2-hydroxy-N-[4-(trifluoromethyl)phenyl]benzamide and 5-chloro-2-hydroxy-N-[4-(trifluoromethyl)phenyl]benzamide are inhibiting the growth of Mtb at the concentrations of 1 and 2 μM respectively. Current research in the field of novel antituberculotics on their way to the clinic has revealed that many nitro-substituted compounds owe their antimycobacterial activity to the presence of a nitro group in their scaffold. 22, 23 For example, the nitro-reduction of nitroimidazole OPC-67683 (also known as delamanid) 24 and PA-824 25 by F 420 -deazaflavindependent nitroreductase (Ddn) releases nitric oxide, which is thought to inhibit cytochrome oxidase and other targets. In addition, benzothiazinones (BTZ), i.e., BTZ-043 26 and BTZderived inhibitors, i.e., CT139 27 may interact through their nitro-group with a cysteine residue of decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1), either covalently or not, thus blocking the first step in the epimerization reaction of decaprenyl-phosphoryl-D-ribose (DPR) to decaprenyl-phosphoryl-D-arabinose (DPA) the arabinan donor for arabinogalactan. In a similar manner dinitrobenzamides, i.e., DNB1 28 are forming a covalent bond with Cys387 within the active site of DprE1. More recently, novel dinitrobenzyl-bearing benzazole and tetrazole derivatives exhibited high and selective antimycobacterial activity. 29, 30 Herein we describe the influence of the introduction of a nitro-group at the salicylic part of salicylanilides to their antimycobacterial, antimicrobial and antifungal activities. To the best of our knowledge, a structure activity relationship (SAR) concerning the preferable nitrosubstitution of the salicylic part of salicylanilides has not been reported in the literature to date, even if some nitro-substituted salicylanilides have been previously presented. 16, 21, [31] [32] [33] [34] 
Results and Discussion

ADMET properties prediction
The novel salicylanilides were screened in silico, prior to their synthesis, for their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. The software of choice was ADMET Predictor (Simulation Plus, Lancaster, CA), one of the leading computer software for advanced predictive modelling of ADMET properties. 35 The program uses molecular description values as inputs to independent mathematical models (generally, nonlinear machine learning technics) in order to generate estimates for each of the ADMET properties. 36 ADMET Predictor not only rapidly estimates a number of vital ADMET properties from molecular structures, but it is able to validate a series of "ADMET Risk" or "Tox Risk" parameters. They are parameterized to include thresholds for a wide range of calculated and predicted properties that represent potential obstacles to a compound being successfully developed as a drug.
For the majority of the compounds, the analyses indicated no potential risk of either ADME/absorption problems related with physico-chemical properties or any stability risk related to fast hepatic metabolism. Furthermore, no potential interaction related to inhibition of drug biotransformation enzymes was indicated. Most importantly, the tested compounds were not found to be potentially related with toxicity or carcinogenicity as indicated by parameters of acute toxicity and carcinogenicity in rats expressed as TD 50 and LD 50 values, respectively, mutagenic chromosomal aberrations, or maximum recommended therapeutic dose (MRTD).
More specifically, 17 out of 33 compounds showed a preferable ADMET Risk (score 0-2). 5 out of 33 compounds presented an acceptable ADMET Risk (score 3), limited by potential high lipophilicity and absorption related risk. 11 out of 33 compounds showed a nonpreferable ADMET Risk profile (score 4-5). On the other hand, 28 out of 33 compounds showed no potential risk of toxicity (score 0-2) and only 5 out of 33 compounds showed an acceptable risk of toxicity (score 3). There was no direct correlation between the position of the nitro group and the potential risk of toxicity. Furthermore, the substituent on the aniline part is more likely affecting the potential ADMET properties, as halogens in position 3 is preferred while trifluoromethyl group and nitro group are not preferable. The ADMET Risk, as well as the Tox Risk scores of the screened compounds are summarized in Table S1 . With the encouraging prediction results the synthesis of the molecules was decided.
Chemistry
The synthesis of nitro-containing salicylanilides (1-33) is described in Scheme 1. The final compounds were products of the conjugation of nitro-salicylic acids with selected anilines in the presence of PCl 3 under microwave irradiation. All compounds were isolated with good to moderate yields. Scheme 1: Synthesis of nitro-substituted salicylanilides.
Antimycobacterial activity
The nitro-containing salicylanilides (1-33) were evaluated to determine their in vitro antimycobacterial activity against Mycobacterium tuberculosis 331/88 (i.e., H 37 R V ), and the following nontuberculous mycobacteria: Mycobacterium avium 330/88 and Mycobacterium kansasii 235/80 and 6509/96 (a clinical isolated strain). INH, the first-line anti-TB drug, was chosen for the comparison performed in this study. Table 1 reports their minimum inhibitory concentrations (MICs) as well as their calculated logP values. 
INH = isoniazid
According to the nitro-substitution of the salicylic part, the tested compounds could be divided into three groups: Group 1 includes 3-NO 2 derivatives (1-11); Group 2 includes 4-NO 2 derivatives (12-22); and Group 3 includes 5-NO 2 derivatives (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . It was observed that the most preferable position of nitro-group is position 4 of the salicylic part, followed by the nitro-substitution in position 5. Nitro-substitution in position 3 of the salicylic part was the least preferable.
Some nitrosalicylanilides exhibited good to moderate activity against Mtb. For the 4-nitro substituted salicylanilides, the activity ranged between 2-32 μM. The best activity was found for 2-hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18) (MIC = 2 μM). The favorable substitutions in the aniline part, regardless of the position of the nitro-group at the salicylic part, were the mono-or bis-trifluoromethyl-substitution. This is probably due to the increased lipophilicity (higher calculated logP value) of the molecule when bearing the trifluoromethyl moiety and is in accordance with previous results regarding the preferable substitution in the aniline part. 21 
Antibacterial and antifungal activity
Our efforts to further investigate the biological activity of the nitrosalicylanilides, the derivatives that bear the nitro-group in positions 4 and 5 of the salicylic part involved testing against eight bacterial and eight fungal strains. More specifically, the selected molecules were tested against Staphylococcus aureus CCM 4516/08, methicillin-resistant Staphylococcus aureus H 5996/08 (MRSA), Staphylococcus epidermis H 6966/08, Enterococcus sp. J 14365/08, Escherichia coli CCM 4517, Klebsiella pneumoniae D 11750/08, extended spectrum β-lactamases producing Klebsiella pneumoniae J 14368/08, and Pseudomonas aeruginosa CCM 1961. Furthermore, the selected nitrosalicylanilides were tested against four Candida strains (Candida albicans ATCC 44859, Candida tropicalis 156, Candida krusei E28, and Candida glabrata 20/I), Trichosporon asahii 1188 and three filamentous fungi (Aspergillus fumigatus 231, Absidia corymbifera 272, and Trichophyton mentagrophytes 445). Benzylpenicillin (PNC) and fluconazole (FLU) were used for comparison during antibacterial and antifungal activity studies respectively.
Similar to their antimycobacterial activity, 4-nitro substituted salicylanilides were found to be more active against all different Staphylococcus species than their 5-nitro substituted analogues ( Table 2 ). The range of MIC values were between 1-62.5 μM and 3.9-500 μM, respectively. The 3,5-bis(trifluoromethyl) moiety was the best substitution for the aniline part for all the different Staphylococcus species tested. The most active compound against all different Staphylococcus species was N- [3,5- None of the tested compounds was found to be active against any of the tested Gramnegative bacteria (Table S2 ). In addition, nitrosalicylanilides were not found to possess any considerable antifungal activity (Table S3 ).
Cytotoxicity evaluation
12 of the synthesized nitrosalicylanilides were evaluated for their cytotoxic properties using an MTT assay in the HepG2 cell model. HepG2 cells represent the most likely target tissue of antituberculotics-related toxicity, which often complicates the treatment of TB. 37 The tested compounds were chosen according to their antimycobacterial activity and the position of the nitro-group in the salicylic part. More specifically, 4 compounds from each different nitro-substitution of the salicylic part were selected for cytotoxicity experiments. The substitution for the aniline part was: 3,4-diCl, 3-CF 3 , 4-CF 3 and 3,5-diCF 3 . The cytotoxicity results as well as the selectivity indexes (SI) for the tested compounds are summarized in Table 3 . The IC 50 values for the tested compounds were in the range of 1.2 to 13.9 μM. According to the position of the nitro group, 4-nitro substituted salicylanilides showed consistently the lowest IC 50 values (1.2-4.4 μM), while the 3and 5-nitro-substituted analogues showed higher IC 50 values (3.5-13.9 μM). The highest rate of cytotoxicity was found for 2-hydroxy-4nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18) . On the other hand, the highest IC 50 was found for N- [3,5-bis(trifluoromethyl) phenyl]-2-hydroxy-5-nitrobenzamide (33) . There is no direct correlation between the substitution at the aniline part and cytotoxicity. SI values for the tested compounds was always ≤ 1.113 indicating that antimycobacterial activity trends with cytotoxicity.
Conclusions
In order to investigate the influence of the introduction of a nitro group at the salicylic part of salicylanilides on their antimycobacterial, antimicrobial and antifungal activities, a series of novel salicylanilides, containing nitro group in their salicylic part, were designed and synthesized. All compounds were screened in silico with ADMET Predictor prior to their synthesis, in order to obtain an estimated prediction about their potential ADME properties and toxicity risk. The prediction revealed no potential risk of either ADME/absorption problems related with physico-chemical properties or any stability risk related to fast hepatic metabolism for the majority of the screened compounds. In addition the nitrosalicylanilides showed minimum to acceptable risk of toxicity as indicated from their Tox Risk score.
The synthesized compounds were evaluated for their antimycobacterial activity against Mtb and found to possess activity in the low micromolar range, comparable with the 5halogenated salicylanilides which are the most active salicylanilides presented to date. The most preferable position of nitro-group was found to be position 4 of the salicylic part, followed by the nitro substitution in position 5. Nitro substitution in position 3 of the salicylic part was the least preferable. Although nitro-substituted salicylanilides did not show any considerable activity against M. avium, they were more active than INH against M. kansasii 235/80. 2-hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18) was found to possess similar activity with INH against M. kansasii 6509/96. Furthermore, 4-nitro substituted salicylanilides were found to be more active against all Staphylococcus species tested than their 5-nitro substituted analogues while none of the nitrosalicylanilides presented considerable activity against Enterococcus sp. J 14365/08. In addition, the synthesized compounds were found to be inactive against all tested Gram-negative bacteria and fungi. Nitro substituted salicylanilides were found to share a non-preferable cytotoxic profile as their IC 50 values against HepG2 cells were found to be in the range of their MIC values.
The presence of a free phenolic hydroxyl at the salicylanilide scaffold has been suggested to be responsible for the cytotoxicity of these molecules. 16 Several derivatives of salicylanilides have been proved to retain their activity while possessing a less cytotoxic profile. 20, 38 Under this concept, 4-nitrosalicylanilides could be potential candidates for further development by preparing their 4-(substituted)benzoates. This method was previously reported by our group for 5-halogenated salicylanilides affording the more active salicylanilide (4-substituted)benzoates with a preferable cytotoxic profile than the parent salicylanilides. 20 The only limitation observed for the (4-substituted)benzoates of 5halogenated salicylanilides was their poor solubility in aqueous media. It is expected that the presence of a nitro group at the salicylic part, instead of a halogen, will have a positive impact at the solubility of 4-(substituted)benzoates of 4-nitrosalicylanilides. The suggestion concerning the solubility is in agreement with the comparison of the predicted calculated logP values between 4-(substituted)benzoates of 4-nitrosalicylanilides and 4-(substituted)benzoates of 5-halogenated salicylanilides ( Table S4 ).
Experimental part
Chemistry
General methods
All of the reagents and solvents were purchased from Sigma-Aldrich (Darmstadt, Germany) or Penta Chemicals (Prague, Czech Republic) and used as received. The reactions and the purity of the products were monitored by thin-layer chromatography using a mixture of hexane to ethyl acetate of 4:1 or 2:1 as eluent. The plates were coated with 0.2-mm Merck 60 F254 silica gel and were visualized by UV irradiation (254 nm). The melting points were determined on a Büchi Melting Point B-540 apparatus using open capillaries, and the reported values are uncorrected.
Elemental analysis (C, H and N) was performed on an automatic microanalyser CHNS-O CE instrument (FISONS EA 1110, Milano, Italy). Infrared spectra (ATR) were recorded on a FT-IR spectrometer (Nicolet 6700 FT-IR) in the range of 400-4000 cm -1 . The NMR spectra were measured in DMSO at ambient temperature using a Varian V NMR S500 instrument (500 MHz for 1 H and 125 MHz for 13 C, Varian Comp., Palo Alto, CA, USA) or a Varian Mercury-Vxbb 300 (300 MHz for 1 H and 75.5 MHz for 13 C, Varian, Inc., Palo Alto, CA, USA). The chemical shifts, δ, are given in ppm with respect to tetramethylsilane, which was used as an internal standard. The coupling constants (J) are reported in Hz.
The calculated logP values (ClogP), which are the logarithms of the partition coefficients for octan-1-ol/water, were determined using the CS ChemOffice Ultra program (version 12.0, Cambridge-Soft, Cambridge, MA, USA).
Synthesis
All salicylanilides were synthesized via a previously described method 39 with yields of 60-85%. This microwave assisted syntheses were performed in a microwave reactor (530 W, 600 rpm, MicroSYNTH Milestone) for 30-60 min to reflux. All compounds were purified by recrystallization from ethanol or acetone or mixture of ethanol/acetone. 35, 152.94, 138.38, 138.23, 134.08, 133.30, 130.97, 129.37, 128.75, 122.11, 120.43, 118.73, 94 .59. Anal. Calcd for C 13 ). 13 4.1.2.5. 2-Hydroxy-N-(3,4-dichlorophenyl 
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